[Featured Stock] Korea Pharma Soars on Anemia Treatment Phase 1 Clinical Trial Approval

[Asia Economy Reporter Lee Seon-ae] Korea Pharma's stock surged sharply from the beginning of trading on the 25th. This is interpreted as a result of the approval of the Phase 1 clinical trial plan for the iron deficiency anemia treatment ‘KP-01’.

At 9:35 AM on the 25th, Korea Pharma was trading at 33,400 KRW, up 11.15% compared to the previous trading day. The stock price surged from the opening price of 31,100 KRW to 35,600 KRW.

This is attributed to the approval of the clinical trial for the iron deficiency anemia treatment. Korea Pharma announced the day before that it received approval from the Ministry of Food and Drug Safety for the investigational new drug (IND) application for the anemia treatment ‘KP-01’.

A Korea Pharma official stated, “Through this clinical trial, we aim to confirm the safety and tolerability of KP-01 in Koreans with iron deficiency and, by evaluating the pharmacokinetics of Accrufer (ACCUFER), demonstrate the efficacy of the iron deficiency anemia treatment.”